LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced revised guidance ranges for 2010 total net revenues based on lowered expectation for 2010 U.S. net product revenues from CUBICIN® (daptomycin for injection). The company now anticipates 2010 total net revenues in the range of $634 to $640 Million, reflecting the new guidance range for 2010 U.S. net product revenues of $598 to $605 Million. Guidance for 2010 international revenues is unchanged, at around $25 Million.
